Olaparib (AZD2281, Ku-0059436)

Catalog No.S1060

Olaparib (AZD2281, Ku-0059436) Chemical Structure

Molecular Weight(MW): 434.46

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 83 Publications

18 Customer Reviews

  • CYREN does not regulate repair of replication-induced DSBs. Representative images of chromosomes.

    Nature, 2017, 549(7673):548-552. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Clonogenic survival of cells expressing BARD1(WT)res or BARD1(AAE)res after treatment with olaparib or MMC. Data are means ± s.d., n = 3. EV, empty vector. P values were calculated using two-way ANOVA and multiple comparisons were corrected by the Bonferroni method. ** P < 0.01.

    Nature, 2017, 550(7676):360-365. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • a, IC50 levels of olaparib in EWS–FLI1 mutant cells (n = 17) versus breast cancers (n = 13) or pan-cancer (n = 147) dataset. b, Cell viability of IMR90 and Ewing sarcoma cells with increasing doses of olaparib. Mean ± s.d., n = 3 technical replicates, one-way ANOVA compared to IMR90 cells. c, Cell viability plot demonstrating the role of EWS–FLI1 in mediating exquisite sensitivity to olaparib in U2OS cells transfected with either the oncogene or empty vector; n = 3 transfection replicates.

    Nature, 2018, 555(7696):387-391. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Western blot analysis showing PARylated proteins in cells subject to the indicated PARP inhibitor treatments (5 μM Olaparib and 10 μM NU1025).

    Cell, 2018, 172(3):439-453. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 48 hours, and protein extracts were subjected to western blot analysis with the indicated antibodies.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    SAHA and olaparib synergistically induced apoptosis and compromised DNA repair in the sensitive HCC cells. Cells were treated with 0.5 uM SAHA, 3 uM olaparib alone or in combination for 24 (A) or 12 (B) hours, subjected to staining with propidium iodide (A) or FITC-Annexin V (B), and then analyzed by flow cytometry.

    Hepatology 2012 55, 1840-1851. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

     

    Mechanism of FK866/olaparib synergy. FK866 exacerbates levels of gH2AX caused by olaparib. CAL51 cells were exposed to FK866 and/or olaparib for 48 h and cell lysates generated and immunoblotted for total and gH2AX.

    EMBO Mol Med 2012 4, 1087-1096. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Role of PARP and BER in the synergy between PTX and GMX in A549 cells. A) Cells were pre-treated +/- 1 uM olaparib (2h) then sequentially +/- 150nM PTX (24h) then +/- GMX 12nM (48h). Cells were harvested for (left) NAD+ quantification by LC-MS/MS (mean +/-SD of quadruplicates) or (right) viability by CellTiter-Glo (mean +/-SD of duplicates) B) PAR modification of proteins and γ-H2AX levels were measured in extracts treated as in A) by western blotting.

    Cancer Res 2014 74(21), 5948-54. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    J Exp Clin Cancer Res 2013 32(1), 95. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • (A) Representative confocal microscopy images of nuclear γ-H2AX (red) and DAPI (blue) staining in FKO1 cells 30 minutes following irradiation. Cells pre-treated for 24hr with 1μM NanoOlaparib, olaparib, or a vehicle control before irradiation.

    Mol Cancer Ther, 2017, 16(7):1279-1289. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    MSH3-deficient cells are sensitive to olaparib, a PARP inhibitor, and the combination with oxaliplatin. A, clonogenic survival of HCT11635, G5 without doxycycline (DOX), and G5 cells with doxycycline, which were treated with 2 μM of oxaliplatin, 2 μM of olaparib, and the combination of these two drugs. B, clonogenic survival of HT29 cells, which were treated with 1 μM oxaliplatin, 2 μM olaparib, and the combination of these two drugs.

     

     

    J Biol Chem 2011 286, 12157-12165. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Nucl Med Commun 2011 32, 1046-51. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046–1051 . Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Olaparib inhibited cell proliferation, and CRC cells with high XRCC2 expression had higher olaparib sensitivity. The surviving fractions of SW480 cells treated with (A) 1 mM, (B) 10 mM, and (C) 50 mM olaparib were measured using CCK-8. (D) The relation between cell viability and olaparib concentration.

    Medicine (Baltimore) 2014 93(28), e294. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor AZD2281 upon induction of DNA damage Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor AZD2281 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor. Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.

    2010 Dr. David Schrmann from University of Base. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

    Effect of AZD 2281 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     

     

    2010 Dr. Xiangbing Meng of University of Iowa. Olaparib (AZD2281, Ku-0059436) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.
Features A potent PARP inhibitor (currently in late stage clinical trials).
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
1 nM 5 nM
In vitro

Olaparib would act against BRCA1 or BRCA2 mutations. Olaparib is not sensitive to tankyrase-1 (IC50 >1 μM). Olaparib could ablate the PARP-1 activity at concentrations of 30-100 nM in SW620 cells. Olaparib is hypersensitive to BRCA1-deficient cell lines (MDA-MB-463 and HCC1937), compared with BRCA1- and BRCA2-proficient cell lines (Hs578T, MDA-MB-231, and T47D). [1] Olaparib is strongly sensitive to KB2P cells due to suppression of base excision repair by PARP inhibition, which may result in the conversion of single-strand breaks to double-strand breaks during DNA replication, thus activating BRCA2-dependent recombination pathways. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KP3.33 M1Hnbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rVN|Qh\A>? NYLPWZRpUUN3ME21MlcxPSBizszNJC=> MnLyNVg2PTl4MUO=
KP6.3 NFrwXIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUG0JIQ> NIjJUnVKSzVyPUGwMlQzQCEQvF2g M4HQfFE5PTV7NkGz
KP7.7 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDNPFU1KGR? NXzHXGNTUUN3ME21O{BvVSB? MljtNVg2PTl4MUO=
KB2P3.4 NEC2W4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DxSlQh\A>? M2S1PGlEPTB;MUK0JG0h NWWydnR5OTh3NUm2NVM>
KB2P1.21 M1fGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3oU4NqPCCm NFz1VGNKSzVyPUi5NFchdk1i Ml76NVg2PTl4MUO=
U373-MG MUPDfZRwfG:6aXOgRZN{[Xl? MXGxJO69VSB? MV6yOEBp M2fNeWlv[3KnYYPld{Bz[WSrYYTpc44he2Wwc3n0bZZqfHl? NU\DXGN2OTh7NUS3NVI>
T98G NFWxSWdEgXSxdH;4bYMhSXO|YYm= MkO5NUDPxE1i MnLLNlQhcA>? NHOxR5FKdmO{ZXHz[ZMhemGmaXH0bY9vKHOnboPpeIl3cXS7 NUXId5VSOTh7NUS3NVI>
U87-MG MnnPR5l1d3SxeHnjJGF{e2G7 M2nKVlEh|ryPIB?= MlvyNlQhcA>? NUfOXoV6UW6lcnXhd4V{KHKjZHnheIlwdiC|ZX7zbZRqfmm2eR?= MlzPNVg6PTR5MUK=
UVW MYDDfZRwfG:6aXOgRZN{[Xl? MWO1NFAhdk1? NW\afGp5OjRiaB?= MofBTY5kemWjc3XzJJJi\GmjdHnvckB{\W6|aYTpeol1gQ>? NF7vPVQyQDl3NEexNi=>
HeLa MkjJSpVv[3Srb36gRZN{[Xl? MlWzOVAxKG6P MV:0JIg> NVjxfZdiS2G3c3XzJIEhdW:mZYP0JIRmdGG7IHnuJJJmcm:rbnnu[{Bw\iC{YXTpZZRqd25vaX7keYNm\CCGTlGgZpJm[Wu| NX;iSopUOTh7NUS3NVI>
HeLa NVzKUFI2TnWwY4Tpc44hSXO|YYm= NWnkUJVDOSEQvF2g NFPkZ3IzPCCq MoT5SY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG|ZTDhdpJme3R? NIKxOooyQDl3NEexNi=>
T98G M4jYVGZ2dmO2aX;uJGF{e2G7 M4C2dVEh|ryPIB?= MXGyOEBp MkfPSY5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgV{1xcGG|ZTDhdpJme3R? MVixPFk2PDdzMh?=
L3 NXPN[lZ[S3m2b4TvfIlkKEG|c3H5 NVPUbVZPPSEQvF2g NHPDcIw6PiCq NGTmfVFFVVOR MkTFV4lodmmoaXPhcpRtgSCrbnjpZol1eyClZXzsJJN2en[rdnHs M2X0XlIxOTJ2NEW5
Granta-519 NXe1WlNUS3m2b4TvfIlkKEG|c3H5 MWS1JO69VSB? NX\aXI5WQTZiaB?= MYPEUXNQ NU\BV2dPW2yrZ3j0cJkhcW6qaXLpeJMh[2WubDDzeZJ3cX[jbB?= MV[yNFEzPDR3OR?=
BT NEjrTYNEgXSxdH;4bYMhSXO|YYm= MoT4OUDPxE1i Moq2PVYhcA>? M1vXUGROW09? MY\TcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt Mm\ZNlAyOjR2NUm=
UPN2 MXXDfZRwfG:6aXOgRZN{[Xl? NV\US2pKPSEQvF2g M4LabFk3KGh? NHvTc21FVVOR MWrTcIlocHSueTDpcohq[mm2czDj[YxtKHO3co\peoFt NWjZdWpROjBzMkS0OVk>
HBL-2 NHi3UnVEgXSxdH;4bYMhSXO|YYm= NXjGUJQzPSEQvF2g NFHqc5U6PiCq NX7aU5pOTE2VTx?= NF3RToRUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu NW[wfFZsOjBzMkS0OVk>
JVM-2 MmizR5l1d3SxeHnjJGF{e2G7 MlyxOUDPxE1i MWO5OkBp MUjEUXNQ MoXJV4xq\2i2bImgbY5pcWKrdIOgZ4VtdCC|dYL2bZZidA>? NHPzU3kzODF{NES1PS=>
Z138 MlfyR5l1d3SxeHnjJGF{e2G7 MUK1JO69VSB? Mmr3PVYhcA>? NW\sUWJpTE2VTx?= NIPGPIRUdGmpaITsfUBqdmirYnn0d{Bk\WyuIIP1dpZqfmGu M2O2fVIxOTJ2NEW5
RWPE NVHMXJc6UW64YYPpeoUhSXO|YYm= MoO4NlUh|ryP NUHrVZhGPDhiaB?= MVXEUXNQ MUjTbYdvcW[rY3HueIx6KHKnZIXj[ZMhTVKJLXTybZZmdiClZXzsJIlvfmG|aX;u NG\DfZozOTV5NUi2OS=>
VCaP MV\JcpZie2m4ZTDBd5NigQ>? MnXONlUh|ryP MlLlOFghcA>? M{jjUWROW09? NUDmfGJYW2mpbnnmbYNidnSueTDy[YR2[2W|IFXSS{1lemm4ZX6gZ4VtdCCrbo\hd4lwdg>? NGXkPXAzOTV5NUi2OS=>
Mouse H2AX−/− ES Cells NFP5Wo9EgXSxdH;4bYMhSXO|YYm= NXr2XGtiOi53IN88US=> MXeyNEBp MUXTbYdvcW[rY3HueIx6KGmwaHnibZR{KGOnbHygd5Vzfmm4YXy= M2\SZlI{OzV3NEi5
Mouse ATM−/− ES Cells MXvDfZRwfG:6aXOgRZN{[Xl? NUTzTJc1Oi53IN88US=> MkLlNlAhcA>? NVW3SIQ3W2mpbnnmbYNidnSueTDpcohq[mm2czDj[YxtKHO3co\peoFt M2f4TVI{OzV3NEi5
H1650 M{HyVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XlflIxKM7:TR?= MYqxOFQhcA>? MX7JR|UxRTF3LkS3JO69VQ>? NFP6bZQzOzJ|OUiwPS=>
H1650PTEN+ MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrMN45FOjBizszN MXWxOFQhcA>? MkfFTWM2OD13MD64N{DPxE1? MofaNlMzOzl6MEm=
PC-9 MmC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDaboNSOjBizszN M3HGdlE1PCCq MWXJR|UxRTVwOEig{txO MmDTNlMzOzl6MEm=
PC-9PTEN− MoS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3i0blIxKM7:TR?= NFPRd|kyPDRiaB?= M1fIeWlEPTB;Nj61NkDPxE1? MlK4NlMzOzl6MEm=
MDA-MB-231 M1u2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q4fVUh\GG7 M132b2lEPTB;Nj65JO69VQ>? MXeyN|c3ODR7Nh?=
MDA-MB-468 NVvrW|hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW1JIRigQ>? M1XSZmlEPTB;NT6wJO69VQ>? NXO3cogxOjN5NkC0PVY>
BT20 MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXO1JIRigQ>? NVT2TItQUUN3ME23Mlch|ryP M3m4S|I{PzZyNEm2
HCC1143 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTBcW5NPSCmYYm= NUXFUpQ4UUN3ME2xNU4yKM7:TR?= M4rkcFI{PzZyNEm2
HCC1937 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFT6Z3I2KGSjeR?= MWDJR|UxRTF{Lk[g{txO NYPZNIlUOjN5NkC0PVY>
Hs578t Ml:xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvnbow2KGSjeR?= M1TCdWlEPTB;NT62JO69VQ>? Mln4NlM4PjB2OU[=
Hs578t(si) MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;OenFUPSCmYYm= M3zqcmlEPTB;Nz61JO69VQ>? MkTKNlM4PjB2OU[=
BT474 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHQTmtrPSCmYYm= Mmm2TWM2OD1zOT64JO69VQ>? MW[yN|c3ODR7Nh?=
JIMT1 NFvMe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL3OUBl[Xl? Mm[wTWM2OD15Lkeg{txO NEfx[ogzOzd4MES5Oi=>
SKBR3 M1fxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVi1JIRigQ>? M3XUOGlEPTB;MUGuNUDPxE1? NUPwdZREOjN5NkC0PVY>
SUM159 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjWZ5g2KGSjeR?= NW\MPI5JUUN3ME20MlIh|ryP M1zOTVI{PzZyNEm2
CAMA1 NGf3TWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr1NXE2KGSjeR?= NX\EUngyUUN3ME2xOU45KM7:TR?= MXOyN|c3ODR7Nh?=
MCF7 NXL3OoRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjNc|hCPSCmYYm= MUPJR|UxRTVwODFOwG0> M2fsUFI{PzZyNEm2
T47D MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDnPVdJPSCmYYm= M2rvV2lEPTB;OT62JO69VQ>? NFfpOoczOzd4MES5Oi=>
HCT116 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTYbYtsOTByIN88US=> NX33XpJEPDhiaB?= Ml7WSG1UVw>? M37QWmlEPTB;Mj61JO69VSB? MVKyOFU4Pzl2MR?=
SW1116 NIft[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVmzV4NVOTByIN88US=> NG\hcJA1QCCq NWrEfVhCTE2VTx?= MUHJR|UxRTFyMDFOwG0> NWPMdJFlOjR3N{e5OFE>
HT29 M4XPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TKNFExOCEQvF2= NHmwNVY1QCCq NV\tV4I3TE2VTx?= NFfsUY9KSzVyPUG0Mlch|ryP NHTEUFczPDV5N{m0NS=>
LoVo NWrLPXlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELs[|cyODBizszN NGTqdmI1QCCq M3XPfGROW09? NF\0b|BKSzVyPUGzMlQh|ryP M{SwdVI1PTd5OUSx
HCT-15 NUDONZdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETKVFcyODBizszN Mm[5OFghcA>? MkG2SG1UVw>? MWfJR|UxRTFyIN88US=> NGjmdHYzPDV5N{m0NS=>
SW48 NGHoW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S0flExOCEQvF2= M2HDUFQ5KGh? MVvEUXNQ MUnJR|UxRTlwNTFOwG0> M1\5RlI1PTd5OUSx
C-1 Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrSV|YyODBizszN NXrHPVg4PDhiaB?= M2XTN2ROW09? M1j1cGlEPTB;Nz62JO69VQ>? NEDsc4QzPDV5N{m0NS=>
RKO NWj3T21uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq0UYJrOTByIN88US=> M{nUVVQ5KGh? NGXjbG9FVVOR Mle0TWM2OD13Lkmg{txO M3zWOFI1PTd5OUSx
HCT116 M2fHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rp[|ExOCEQvF2= M{DFclQ5KGh? NU[1NmlOTE2VTx?= MlTmVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? MVOyOFU4Pzl2MR?=
SW1116 NGfmd5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrCNVAxKM7:TR?= NH\oc5g1QCCq NFS3V|VFVVOR MlTwVI91\W62aXH0[ZMhW05vM{igZ5l1d3SxeHnjbZR6KA>? M1LhfFI1PTd5OUSx
HT29 NE\BRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPCTGZZOTByIN88US=> NYSzToI5PDhiaB?= NX;Ge|BtTE2VTx?= NWTZc2l{WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= Mlm0NlQ2Pzd7NEG=
LoVo Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUmxNFAh|ryP NUTCdGsxPDhiaB?= MoL4SG1UVw>? NFL1XXBRd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli NIDpOWkzPDV5N{m0NS=>
SW48 M2rnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPq[YE1OTByIN88US=> NITBTlA1QCCq M2PYNmROW09? NUTaWpY4WG:2ZX70bYF1\XNiU16tN|gh[3m2b4TvfIlkcXS7IB?= NIfVXWQzPDV5N{m0NS=>
C-1 NGnrW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TGSVExOCEQvF2= M{DBblQ5KGh? MkDwSG1UVw>? M2nFOXBwfGWwdHnheIV{KFOQLUO4JIN6fG:2b4jpZ4l1gSB? NIHrUpkzPDV5N{m0NS=>
RKO M3u2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PVXFExOCEQvF2= MY[0PEBp MWDEUXNQ NEWwbG9Rd3SnboTpZZRmeyCVTj2zPEBkgXSxdH;4bYNqfHli MYmyOFU4Pzl2MR?=
HCT116 MX;GeY5kfGmxbjDBd5NigQ>? M4H5WFExKG6P M2DDc|EzKGh? MmPKSG1UVw>? NEjzNWpKdmO{ZXHz[ZMhTE6DIHTveYJt\S2|dILhcoQh[nKnYXvzJIlv\HWlZXSgZpkhW05vM{i= NEPaTmwzPDV5N{m0NS=>
HT29 NX;leYtiTnWwY4Tpc44hSXO|YYm= MoC4NVAhdk1? MVuxNkBp MmnhSG1UVw>? NWPBZYlQUW6lcnXhd4V{KESQQTDkc5VjdGVvc4TyZY5lKGK{ZXHrd{BqdmS3Y3XkJIJ6KFOQLUO4 MnfpNlQ2Pzd7NEG=
TE-6 MXfGeY5kfGmxbjDBd5NigQ>? NUPRN5lLPSEQvF2g M4XwR|EzKGh? MXLEUXNQ NUP1SXdrUW6mdXPld{BIOi:PIHHydoV{fA>? NXrhXZIzOjR{MUmxOlQ>
TE-6 NHLzT2FHfW6ldHnvckBCe3OjeR?= MkLqOUDPxE1i NV;mcoJuOjRiaB?= NFXxeGVFVVOR NI\aWmNKdmO{ZXHz[ZMhcW5iZH;1ZoxmKHO2cnHu[EBjemWja4OgLGRUSnNr MV2yOFIyQTF4NB?=
Hep3B MnLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLaOFAh|ryPIB?= MlfaO|IhcA>? NXT6SI42TE2VTx?= NWLQVlU5W3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF? NUfLS5B6OjVyN{K3OVI>
Huh7 NVjoZnR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vk[|QxKM7:TTC= MmjlO|IhcA>? NFXBT2JFVVOR NXfDRZBNW3mwZYLnbZN1cWOjbHz5JIlvcGmkaYTzJINmdGxiZ4Lve5RpKHerdHigSGhOTVF? NWTicGRiOjVyN{K3OVI>
Hep3B MV\GeY5kfGmxbjDBd5NigQ>? M3fuZlQxKM7:TTC= M3L1bVI1KGh? NXraVZdJTE2VTx?= MkW3TY5lfWOnczDSU3MheHKxZIXjeIlwdiC5aYToJGRJVUWT NH31bGMzPTB5Mke1Ni=>
Huh7 NVXVNJprTnWwY4Tpc44hSXO|YYm= NW\VWXg3PDBizszNJC=> NUjrV4RZOjRiaB?= M1nrRWROW09? NIjlVZVKdmS3Y3XzJHJQWyCycn;keYN1cW:wIIfpeIghTEiPRWG= NGjWNoczPTB5Mke1Ni=>
Hep3B MXrGeY5kfGmxbjDBd5NigQ>? M4nvXFQxKM7:TTC= MYSyOEBp M1nxXmROW09? MYLJcoR2[2W|IHPlcIwh[XW2b4DoZYd6KHerdHigSGhOTVF? MmXVNlUxPzJ5NUK=
Huh7 MkKySpVv[3Srb36gRZN{[Xl? MXK0NEDPxE1i NHP2VIgzPCCq M1O5SmROW09? M{OzTmlv\HWlZYOgZ4VtdCCjdYTvdIhi\3lid3n0bEBFUE2HUR?= NWfJNmVqOjVyN{K3OVI>
SGC-7901 NXGxWm5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITRZpM{OMLizszN MnjqOFghcA>? NIX3S5lFVVOR MUjCcI9kcyCxeHHsbZBt[XSrbj3pcoR2[2WmIHPlcIwh\GWjdHi= MXeyOVc3PzB5Nh?=
COLO-800 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHBTXpqUUN3ME2wMlQ1OTZ2IN88US=> MWXTRW5ITVJ?
EoL-1- Ml33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq2TWM2OD1yLkW2OFQ3KM7:TR?= MkTDV2FPT0WU
NCI-H209 M4jB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXXZZY1UUN3ME2wMlkyPTV4IN88US=> M1zVU3NCVkeHUh?=
ES1 NXHYR4tYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTQTWM2OD1zLkGxOFA5KM7:TR?= M37qc3NCVkeHUh?=
NKM-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFwMkWzOFch|ryP NIjw[GNUSU6JRWK=
NTERA-S-cl-D1 M2W4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi0e|dKSzVyPUGuN|M{PDFizszN NFKweFhUSU6JRWK=
MHH-ES-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHvR3lrUUN3ME2xMlYzODZ5IN88US=> NEC5UZRUSU6JRWK=
ES8 NEXieo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljQTWM2OD1zLkeyOFE1KM7:TR?= MYPTRW5ITVJ?
NCI-H720 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rCbGlEPTB;Mj6yNFY6QSEQvF2= MULTRW5ITVJ?
EW-3 NFT4PJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTMZ4RKSzVyPUKuNlc2OzRizszN MmTKV2FPT0WU
D-566MG MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXJcmxKSzVyPUKuOFQ2PjhizszN NY\HZWhZW0GQR1XS
697 NYPD[mlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLLWYZKSzVyPUKuPFQyPzNizszN Mn\NV2FPT0WU
ES5 NEPH[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[0TWM2OD1{Lki4NVg6KM7:TR?= M4nyd3NCVkeHUh?=
COLO-684 NXnSfYJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[3SWgzUUN3ME2zMlUyPjl4IN88US=> MXHTRW5ITVJ?
ML-2 NF7w[VNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\pNIxFUUN3ME2zMlYxODV6IN88US=> NGPlT|NUSU6JRWK=
MC-IXC MkPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\iTWM2OD1|Lk[zN|k{KM7:TR?= M3n2NXNCVkeHUh?=
DB NVrVXWZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLzTWM2OD1|Lk[1OFQ5KM7:TR?= NWjZPFdnW0GQR1XS
HCC2218 M1zhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDROVhGUUN3ME2zMlc{OTB|IN88US=> NFHYTpVUSU6JRWK=
NCI-H510A MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7ZTWM2OD1|LkiyO|I1KM7:TR?= NUTFc3ZFW0GQR1XS
NCI-H526 NHvj[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTNwOE[5OVgh|ryP MlLIV2FPT0WU
MV-4-11 NHfB[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1S0c2lEPTB;ND6xN|M{PCEQvF2= MmXnV2FPT0WU
PA-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTRwMkWyPUDPxE1? NG\CbHVUSU6JRWK=
EW-22 M2\t[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T2fmlEPTB;ND6zOVg3KM7:TR?= NV3lb3p1W0GQR1XS
KASUMI-1 NYDKUFdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXDN5dKSzVyPUSuOFAyODlizszN Mlz4V2FPT0WU
LU-139 NFzFOI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO2VnBjUUN3ME20Mlc2QDJ7IN88US=> NHTMbW9USU6JRWK=
SBC-1 MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvrTWM2OD12LkiwPVA5KM7:TR?= M3PyenNCVkeHUh?=
H4 MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn63TWM2OD12Lki5OFQ{KM7:TR?= NEe4eItUSU6JRWK=
EW-11 NUP4R45wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES4[JRKSzVyPUWuNFgxPzJizszN NGjIOWhUSU6JRWK=
NBsusSR MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXLTWM2OD13LkGyNFU2KM7:TR?= NVf6dWo6W0GQR1XS
RPMI-8226 NEKxWnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;lTWM2OD13LkG1NlQ1KM7:TR?= NV3sVWFiW0GQR1XS
DEL Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTReHVKSzVyPUWuNlAxODZizszN NEHJNm5USU6JRWK=
ES4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPHSXVqUUN3ME21MlUyOzh7IN88US=> NX;oXGp6W0GQR1XS
GCT MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jGVWlEPTB;NT61Olg2PiEQvF2= MmrFV2FPT0WU
NCI-H1048 M1iwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nyU2lEPTB;NT65O|I4OyEQvF2= NFzlbmdUSU6JRWK=
NCI-SNU-1 Mk[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H5WmlEPTB;Nj6wNlIh|ryP Ml;jV2FPT0WU
ES7 NXX0VoF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTZwMEO1O|ch|ryP MofEV2FPT0WU
SW982 MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTCTWM2OD14LkC5NVM4KM7:TR?= MWPTRW5ITVJ?
L-363 M1ztSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK4XVFFUUN3ME22MlM{QTd2IN88US=> MX7TRW5ITVJ?
HT-1080 M3vteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljtTWM2OD14LkS5Olg{KM7:TR?= NVjNUpV3W0GQR1XS
HAL-01 NXjuOnZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPNcI9vUUN3ME22MlUyODlizszN NFPwWYdUSU6JRWK=
NB14 MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzYc5J{UUN3ME22MlY1ODN7IN88US=> NEixU|VUSU6JRWK=
EW-13 NIfiOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf6UY5KSzVyPU[uO|c1OjRizszN M2fyNHNCVkeHUh?=
NY NYSxdVZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPoTWM2OD14Lkm0OlA2KM7:TR?= M1zTcXNCVkeHUh?=
NCI-SNU-5 M{fr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTdwMUC0N|Mh|ryP NVLSe2MzW0GQR1XS
MS-1 M1naWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTdwMUe0PVQh|ryP NHPxZoJUSU6JRWK=
EW-16 Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoL4TWM2OD15LkOxPFYyKM7:TR?= NFXXeWFUSU6JRWK=
LU-65 NV3VcIVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHvTWM2OD15LkS4OFE4KM7:TR?= MoT4V2FPT0WU
HGC-27 NVW0NZdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTdwN{KxO|Mh|ryP MWfTRW5ITVJ?
CTB-1 NYPjcW5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTdwN{[xO|Uh|ryP M2DZcXNCVkeHUh?=
5637 NGT5WWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTdwOUK4OkDPxE1? Mln5V2FPT0WU
U251 MmjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTdwOUSwNVYh|ryP MU\TRW5ITVJ?
HOS MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTxe4dIUUN3ME24MlI{ODB5IN88US=> M1zob3NCVkeHUh?=
DOHH-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRThwMkO1PEDPxE1? NFzWdWdUSU6JRWK=
EW-1 M2DxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRThwM{CwPFgh|ryP MWXTRW5ITVJ?
BV-173 NX76ZXFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC0PXg3UUN3ME24MlU2PTRizszN MV3TRW5ITVJ?
8-MG-BA MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj4eotKSzVyPUiuOlg6QDhizszN NHSxXGdUSU6JRWK=
NB69 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XnUmlEPTB;OD63NFkzOSEQvF2= M1e5NnNCVkeHUh?=
NCI-H69 NVnFd|Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTlwOUC5OlEh|ryP MlSwV2FPT0WU
RS4-11 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnDXHBUUUN3ME2xNU4zOjB6IN88US=> M13rcnNCVkeHUh?=
ONS-76 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDLTWM2OD1zMT6yPVQ4KM7:TR?= MWLTRW5ITVJ?
SF539 NWfwVIdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTVTWM2OD1zMT60PFg6KM7:TR?= NEDGfHNUSU6JRWK=
HuO-3N1 NVz3cJhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\2OoxvUUN3ME2xNU42Pzl4IN88US=> M3riPHNCVkeHUh?=
NCI-H1651 Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTFTWM2OD1zMj6zNVE2KM7:TR?= NFjxfnVUSU6JRWK=
KARPAS-45 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\NeWlEPTB;MUKuN|c3KM7:TR?= NGfTPGtUSU6JRWK=
SK-NEP-1 NHXmWHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3RZlNHUUN3ME2xNk41PjB7IN88US=> Ml\sV2FPT0WU
LAMA-84 M4jwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnP3TWM2OD1zMz6xNFk2KM7:TR?= Ml7rV2FPT0WU
NCI-H1155 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni3TWM2OD1zMz6yPFU3KM7:TR?= MmqyV2FPT0WU
CTV-1 MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF|LkS0OUDPxE1? NF7KSpdUSU6JRWK=
QIMR-WIL MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfI[4NKSzVyPUGzMlc5OTRizszN MoCzV2FPT0WU
H9 NXHDUGdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHkcJBPUUN3ME2xN{45PDd3IN88US=> MYXTRW5ITVJ?
SK-MEL-1 NITqXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\pOGlEPTB;MUOuPVM1PyEQvF2= Mm\6V2FPT0WU
HD-MY-Z MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfx[JduUUN3ME2xOE4xPjN5IN88US=> NG\pTWlUSU6JRWK=
TI-73 NFXuWHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF2LkKzOVYh|ryP M3u1OHNCVkeHUh?=
JVM-3 NVzhfnhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7vTWM2OD1zNT61O|E3KM7:TR?= Mn;ZV2FPT0WU
D-247MG NFvtPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7GS3dKSzVyPUG1MlU6OyEQvF2= MX\TRW5ITVJ?
VA-ES-BJ MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXLc5hwUUN3ME2xOU43ODl5IN88US=> MYXTRW5ITVJ?
NOS-1 NX:1OYxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPtTWM2OD1zNT62OVIzKM7:TR?= NVjCVJdnW0GQR1XS
MOLT-4 MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn1TWM2OD1zNj63OVIh|ryP M2LLUnNCVkeHUh?=
Mo-T NVLDXY85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTF5LkC4OFkh|ryP NE\jTo1USU6JRWK=
NCI-H1770 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTF5LkG1OFMh|ryP M3r2fnNCVkeHUh?=
COLO-320-HSR NYLm[pd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjrfYlKSzVyPUG3MlE5OjdizszN M3jDSXNCVkeHUh?=
TE-12 MlPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;pVWlEPTB;MUeuO|A2PCEQvF2= M{\GcnNCVkeHUh?=
NCI-H82 NYHIdI9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;3W|ZFUUN3ME2xO{45PzJ6IN88US=> NWf4UZV7W0GQR1XS
NEC8 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTK[WdKSzVyPUG4MlE{OTZizszN NUTGR21QW0GQR1XS
HSC-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK4TWM2OD1zOD63OFE1KM7:TR?= MV\TRW5ITVJ?
NCI-H1092 M4LzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzLTWM2OD1zOD63OVk2KM7:TR?= NGTFV5VUSU6JRWK=
NCI-H292 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF7LkC0PFkh|ryP MXjTRW5ITVJ?
L-428 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fVZ2lEPTB;MUmuOVU6KM7:TR?= NV3JO4d1W0GQR1XS
LU-134-A NG\JNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7rTWM2OD1zOT61O|Ih|ryP NVKzbmJyW0GQR1XS
GI-ME-N NVP0c2gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkSyTWM2OD1zOT61O|Q4KM7:TR?= NWTDVpRQW0GQR1XS
ALL-PO MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T3OWlEPTB;MUmuOVk4OiEQvF2= NYr3ZVlqW0GQR1XS
D-283MED MnPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HRPGlEPTB;MUmuPVE2KM7:TR?= M{fweHNCVkeHUh?=
D-423MG NVjXXI1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\tWo5KSzVyPUG5Mlk6PjdizszN MYHTRW5ITVJ?
CAKI-1 NYr1S4dxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfKTWM2OD1{MD6yNlE6KM7:TR?= MX3TRW5ITVJ?
ETK-1 NEexTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrrTWM2OD1{MD6yOlE2KM7:TR?= MVnTRW5ITVJ?
G-402 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnQXZlKSzVyPUKwMlU{OzRizszN NGfEUVdUSU6JRWK=
HL-60 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILFdINKSzVyPUKxMlE3OTNizszN MmfmV2FPT0WU
A2058 MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rOeWlEPTB;MkGuOFQ4PyEQvF2= MnjLV2FPT0WU
CHP-212 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PEOmlEPTB;MkGuPVA2OSEQvF2= MkLhV2FPT0WU
KY821 NULrXnpNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXOXHA2UUN3ME2yNU46PzVizszN NVyxPZE6W0GQR1XS
TYK-nu MoHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPNTWM2OD1{Mj6wOlUyKM7:TR?= MXLTRW5ITVJ?
JVM-2 M16yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfnPHlKSzVyPUKyMlI6QDNizszN NYns[YVNW0GQR1XS
KU812 NUHEXFliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUH1U2l6UUN3ME2yNk44OzF{IN88US=> NXKw[XZlW0GQR1XS
MKN28 MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\FTWM2OD1{Mj65NFE2KM7:TR?= NF\vNotUSU6JRWK=
ECC10 M13adGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfsdG5SUUN3ME2yN{44PDFizszN NFPWZ3RUSU6JRWK=
BHT-101 M4rRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ2LkCwNFgh|ryP MoXpV2FPT0WU
DU-4475 NXTHO4FiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTJ2LkOzN|ch|ryP MVXTRW5ITVJ?
769-P NYLGb5o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDVTWM2OD1{ND64OFY3KM7:TR?= NYXMSmpzW0GQR1XS
HEC-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe2WY9HUUN3ME2yOU41PDVizszN NVPMVmFrW0GQR1XS
MOLT-13 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4e5fmlEPTB;MkWuOVM{OSEQvF2= M4fSVXNCVkeHUh?=
8505C M17nb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjvTIpKSzVyPUK2MlQ6PzdizszN MWHTRW5ITVJ?
GB-1 NXvCelFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYiwR3d{UUN3ME2yOk44OTd4IN88US=> MVXTRW5ITVJ?
SF126 MlnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3lVHNKSzVyPUK2Mlc3PDhizszN MnT4V2FPT0WU
A4-Fuk MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJ5LkGyO|Eh|ryP M3S4WHNCVkeHUh?=
OVCAR-8 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnYVGl6UUN3ME2yO{4yPTN7IN88US=> NHfuT21USU6JRWK=
NCI-H1304 NV7SXFJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nh[WlEPTB;MkeuOVQh|ryP MnfHV2FPT0WU
GR-ST M{LjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDJNZlKSzVyPUK4MlA1PyEQvF2= MWHTRW5ITVJ?
G-401 MmL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXPRlZwUUN3ME2yPE42ODl4IN88US=> M1Kyb3NCVkeHUh?=
LXF-289 NG\rfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT5TmtiUUN3ME2yPE42PjVzIN88US=> MkTUV2FPT0WU
DBTRG-05MG M2q5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zBPGlEPTB;MkiuPVIxPCEQvF2= NV;QbYVUW0GQR1XS
YKG-1 NVjjPIFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXtT2Y1UUN3ME2yPU45PjhizszN NHLpT4pUSU6JRWK=
GAMG NETNd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTJ7Lkm5N{DPxE1? MX3TRW5ITVJ?
HCT-116 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HqTWlEPTB;M{CuNFU1QCEQvF2= MWTTRW5ITVJ?
S-117 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELYc2JKSzVyPUOxMlIzPTdizszN MWTTRW5ITVJ?
NCI-H1693 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDUe2U6UUN3ME2zN{43PTR{IN88US=> NYHuNWcxW0GQR1XS
A427 NVjrTlRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPuTWM2OD1|Mz65PVc3KM7:TR?= M3rGTnNCVkeHUh?=
HT-29 NYrMN5VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvnTWM2OD1|ND62NFMzKM7:TR?= MWjTRW5ITVJ?
P12-ICHIKAWA NV;RcmlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mli4TWM2OD1|ND63OFkyKM7:TR?= MkC4V2FPT0WU
CAL-51 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPYTWM2OD1|NT6wO|A6KM7:TR?= MVrTRW5ITVJ?
Ramos-2G6-4C10 NH3YVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTN3LkK0NlUh|ryP MXfTRW5ITVJ?
SCH NUHsblRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjQTY05UUN3ME2zOk41OTd2IN88US=> NFP3XHZUSU6JRWK=
SK-MEL-24 NWDwcYJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrscm5KSzVyPUO2MlkxPDRizszN MULTRW5ITVJ?
SW1573 MkDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHEd2RpUUN3ME2zPE44OjF4IN88US=> M1TWdHNCVkeHUh?=
BALL-1 MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrLV|dUUUN3ME2zPU4zOTJ7IN88US=> NF\VVWJUSU6JRWK=
BE-13 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\PcJd{UUN3ME2zPU4{OjlizszN NUS5bYpPW0GQR1XS
GI-1 NIewbFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3KTWM2OD1|OT64OlQ4KM7:TR?= NIi4fYhUSU6JRWK=
GOTO Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LIe2lEPTB;M{muPVE{QSEQvF2= NUnsTFg6W0GQR1XS
A673 M2jqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHF[GVKSzVyPUSxMlA{PDNizszN MUDTRW5ITVJ?
KG-1 M2C1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTR|LkO5OEDPxE1? M2HyOHNCVkeHUh?=
GP5d M3;yXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\TXWlEPTB;NESuNFY3PiEQvF2= MWXTRW5ITVJ?
MFM-223 NYnROndQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3pUHhKSzVyPUS0MlEzOjhizszN M{LyT3NCVkeHUh?=
OAW-42 NV7HSYZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[wbINKSzVyPUS0MlI3PDNizszN NETw[nJUSU6JRWK=
C8166 M{\OZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUW3c3ZVUUN3ME20OU4xQDJ{IN88US=> MVrTRW5ITVJ?
LU-99A M2jDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULGdpBVUUN3ME20Ok4yOzJ{IN88US=> M4\2NHNCVkeHUh?=
NCI-H23 NUPkR|VJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\GTWM2OD12Nj6xO|g2KM7:TR?= MU\TRW5ITVJ?
HO-1-N-1 NU\x[2NsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX3bpdKSzVyPUS3MlA6QThizszN NEnh[IVUSU6JRWK=
A3-KAW NIC1V25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXydmhKSzVyPUS3MlExODdizszN MWPTRW5ITVJ?
CGTH-W-1 NV76UIJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTR5LkWwOlkh|ryP MVzTRW5ITVJ?
DJM-1 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLIZ2JKSzVyPUS3MlU1OTNizszN NIn5RXNUSU6JRWK=
A101D NX3Rb3Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[xSW5KSzVyPUS3MlY{PTdizszN NUD4XVNqW0GQR1XS
BB30-HNC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnyyTWM2OD12OD6zNFczKM7:TR?= NWnqTIVjW0GQR1XS
T98G NIL6NHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rF[2lEPTB;NEiuOFY{OyEQvF2= NHrodHhUSU6JRWK=
NCI-H1573 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm0WZdKSzVyPUS5MlQ1PjJizszN NGDEN2hUSU6JRWK=
MEG-01 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj1dFBKSzVyPUS5Mlc1OTFizszN Mn63V2FPT0WU
WM-115 NUWwVpB4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXflZYczUUN3ME20PU46OjJ{IN88US=> NH76VJpUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Combining with temozolomide, Olaparib (10 mg/kg, p.o.) significantly suppresses tumor growth in SW620 xenografts. [1] Olaparib shows great response to Brca1-/-;p53-/- mammary tumors (50 mg/kg i.p. per day), while no responses to HR-deficient Ecad-/-;p53-/- mammary tumors. Olaparib even does not show dose-limiting toxicity in tumor-bearing mice. [3] Olaparib has been used to treat with BRCA mutated tumors, such as ovarian, breast and prostate cancers. Moreover, Olaparib shows selectively inhibition to ATM (Ataxia Telangiectasia Mutated)-deficient tumor cells, which indicates to be a potential agent for treating ATM mutant lymphoid tumors. [4]

Protocol

Kinase Assay:

[1]

+ Expand

FlashPlate assay (96-well screening assay):

To columns 1 through 10, 1 μL of Olaparib (in DMSO) is added, and 1 μL DMSO only is added to the positive (POS) and negative (NEG) control wells (columns 11 and 12, respectively) of a pretreated FlashPlate. PARP-1 is diluted 1:40 in buffer (buffer B: 10% glycerol (v/v), 25 mM HEPES, 12.5 mM MgCl2,50 mM KCl, 1 mM DTT, 0.01% NP-40 (v/v), pH 7.6) and 40 μL added to all 96 wells (final PARP-1 concentration in the assay is ~1 ng/μL). The plate is sealed and shaken at RT for 15 min. Following this, 10 μL of positive reaction mix (0.2 ng/μL of double-stranded oligonucleotide [M3/M4] DNA per well, 5 μM of NAD+ final assay concentration, and 0.075 μCi 3H-NAD+ per well) is added to the appropriate wells (columns 1-11). The negative reaction mix, lacking the DNA oligonucleotide, is added to column 12 (with the mean negative control value used as the background). The plate is resealed and shaken for a further 60 min at RT to allow the reaction to continue. Then, 50 μL of ice-cold acetic acid (30%) is added to each well to stop the reaction, and the plate is sealed and shaken for a further 60 min at RT. Tritiated signal bound to the FlashPlate is then determined in counts per minute (CPM) using the TopCount plate reader.
Cell Research:

[1]

+ Expand
  • Cell lines: Breast cancer cell lines including SW620 colon, A2780 ovarian, HCC1937, Hs578T, MDA-MB-231, MDA-MB-436, and T47D
  • Concentrations: 1-300 nM
  • Incubation Time: 7-14 days
  • Method:

    The cytotoxicity of Olaparib is measured by clonogenic assay. Olaparib is dissolved in DMSO and diluted by culture media before use. The cells are seeded in six well plates and left to attach overnight. Then Olaparib is added at various concentrations and the cells are incubated for 7-14 days. After that the surviving colonies are counted for calculating the IC50.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: Brca1-/-;p53-/- mammary tumors are generated in K14cre;Brca1F/F;p53F/F mice.
  • Formulation: 50 mg/mL stocks in DMSO with 10% 2-hydroxyl-propyl-β-cyclodextrine/PBS
  • Dosages: 50 mg/kg
  • Administration: Administered via i.p. injection at 10 μL/g of body weight
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL warmed (197.94 mM)
Water 0.002 mg/mL (0.0 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.46
Formula

C24H23FN4O3

CAS No. 763113-22-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03462342 Recruiting High Grade Serous Carcinoma University of Pennsylvania|AstraZeneca March 9 2018 Phase 2
NCT03117933 Recruiting Ovarian Cancer University of Oxford|AstraZeneca March 9 2017 Phase 2
NCT03106987 Recruiting Epithelial Ovarian Cancer AstraZeneca|European Network of Gynaecological Oncological Trial Groups (ENGOT) June 8 2017 Phase 3
NCT02484404 Recruiting Lung Cancer|Breast Cancer|Ovarian Cancer|Colorectal Cancer|Prostate Cancer|Triple Negative Breast Cancer National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 8 2015 Phase 1|Phase 2
NCT00679783 Active not recruiting Ovarian Carcinoma|Breast Cancer AstraZeneca|British Columbia Cancer Agency July 8 2008 Phase 2
NCT03008278 Recruiting Gastroesophageal Junction Adenocarcinoma|Recurrent Gastric Carcinoma|Stage IV Gastric Cancer AJCC v7 National Cancer Institute (NCI) November 7 2017 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I saw that the solubility of the compound for in vivo on the website had been changed, why the change has been made?

  • Answer:

    For the formulation for in vivo, the compound dissolving in 15% Captisol (former solubility) is a suspension, and it is fine for oral gavage. And now, dissolving in 4% DMSO+30% PEG 300+ddH2O is a clear solution, and is for injection.

  • Question 2:

    How long can the chemical compound be stable in DMEM at 4 °C?

  • Answer:

    The compound is stable in DMEM at 4 degree for one week.

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) supplier | purchase Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) cost | Olaparib (AZD2281, Ku-0059436) manufacturer | order Olaparib (AZD2281, Ku-0059436) | Olaparib (AZD2281, Ku-0059436) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID